[{"uuid": "1b0f9a03-7baf-387e-b438-d858423d2081", "title": "Astria Therapeutics to Present at Upcoming Western Society of Allergy, Asthma & Immunology Annual Scientific Session", "publisher": "Business Wire", "link": "https://finance.yahoo.com/news/astria-therapeutics-present-upcoming-western-130000736.html", "providerPublishTime": 1738587600, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/cQxm4pXxPko05.CwIWFVPA--~B/aD0xMTg5O3c9Mzk0NTthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/business-wire.com/47fcefb2099498771f81530d7daafe8d", "width": 3945, "height": 1189, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/17995uWMqWtrTffLFvg_yw--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/47fcefb2099498771f81530d7daafe8d", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["ATXS"]}, {"uuid": "8047b3bd-13d5-3d76-bcce-9c760890083f", "title": "Astria Therapeutics' Shares Rise After JMP Securities Initiates Coverage With Outperform Rating", "publisher": "MT Newswires", "link": "https://finance.yahoo.com/news/astria-therapeutics-apos-shares-rise-190153884.html", "providerPublishTime": 1738350113, "type": "STORY"}, {"uuid": "96b1393e-61c7-39e6-a38b-2109e7228089", "title": "JMP Securities Initiates Astria Therapeutics at Outperform", "publisher": "MT Newswires", "link": "https://finance.yahoo.com/news/jmp-securities-initiates-astria-therapeutics-131506488.html", "providerPublishTime": 1738329306, "type": "STORY"}, {"uuid": "73ccb096-a6ff-35b1-9a0d-d9f4188ea24e", "title": "Zillow initiated, Electronic Arts upgraded: Wall Street's top analyst calls", "publisher": "The Fly", "link": "https://finance.yahoo.com/news/zillow-initiated-electronic-arts-upgraded-143244319.html", "providerPublishTime": 1738333964, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/zUit8GQVW5kcaTZHEPMI9Q--~B/aD02Mjg7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/the_fly_169/5039a5ccc6ec98e1b92bc672330bfcec", "width": 1200, "height": 628, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/IPH9wCP.ftudEFOX7xr1MA--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/the_fly_169/5039a5ccc6ec98e1b92bc672330bfcec", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["EA", "ZG", "MDLZ", "CHRW", "MUR"]}, {"uuid": "2257a91b-d020-3d30-9715-5bf3e702c1bf", "title": "Astria Therapeutics Starts Phase 1a Trial of Atopic Dermatitis Treatment", "publisher": "MT Newswires", "link": "https://finance.yahoo.com/news/astria-therapeutics-starts-phase-1a-155836747.html", "providerPublishTime": 1737647916, "type": "STORY"}, {"uuid": "58c268e6-718e-3d0d-b422-3a688a5a7f54", "title": "Astria Therapeutics Announces Initiation of Phase 1a Trial of STAR-0310, a Potential Best-in-Class Monoclonal Antibody OX40 Antagonist for the Treatment of Atopic Dermatitis", "publisher": "Business Wire", "link": "https://finance.yahoo.com/news/astria-therapeutics-announces-initiation-phase-130000212.html", "providerPublishTime": 1737637200, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/rInCtGRHoifTN2GPDUxv1g--~B/aD0xMTg5O3c9Mzk0NTthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/business-wire.com/8d7299a493fc07b5f9de49688b27e501", "width": 3945, "height": 1189, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/ly5NSfau3l4FjKfy5lbp2A--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/8d7299a493fc07b5f9de49688b27e501", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["ATXS"]}, {"uuid": "866baff1-2dd1-3801-8833-942d195e8957", "title": "Astria Therapeutics Announces Design of ALPHA-ORBIT Pivotal Phase 3 Trial of Navenibart in HAE", "publisher": "Business Wire", "link": "https://finance.yahoo.com/news/astria-therapeutics-announces-design-alpha-130000811.html", "providerPublishTime": 1736773200, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/qWBvAuqD0dMK6_5lwdzyLQ--~B/aD0xMTg5O3c9Mzk0NTthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/business-wire.com/fc4b890b8e9b70b5a7e20d90c140e4b0", "width": 3945, "height": 1189, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/ELw2kXDLny6F_A1cgTuqYw--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/fc4b890b8e9b70b5a7e20d90c140e4b0", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["ATXS"]}, {"uuid": "56a5d53f-3bbe-353f-95bd-b0d285878b30", "title": "Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)", "publisher": "Business Wire", "link": "https://finance.yahoo.com/news/astria-therapeutics-announces-inducement-grants-211000555.html", "providerPublishTime": 1735938600, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/qsDDZiMPJJqwN4m2wu_okQ--~B/aD0xMTg5O3c9Mzk0NTthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/business-wire.com/ae14197659ff5e6b93158f391f468f0a", "width": 3945, "height": 1189, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/3IiQcShkHN8P11dixt.xbQ--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/ae14197659ff5e6b93158f391f468f0a", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["ATXS"]}, {"uuid": "6323163e-e18f-38cf-9791-3d5d5623713d", "title": "Is Astria Therapeutics (ATXS) Stock Outpacing Its Medical Peers This Year?", "publisher": "Zacks", "link": "https://finance.yahoo.com/news/astria-therapeutics-atxs-stock-outpacing-144011542.html", "providerPublishTime": 1734446411, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/XxozWWpdDFgGg6m0CzltLg--~B/aD02MDI7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/45c083e4721b0d0d1f6e431ec0bb5cc1", "width": 900, "height": 602, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/HGBb_w3iAqceoCyVMucmoA--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/zacks.com/45c083e4721b0d0d1f6e431ec0bb5cc1", "width": 140, "height": 140, "tag": "140x140"}]}}, {"uuid": "c0f547d8-5749-34e4-a690-53604cd99f7b", "title": "Astria Therapeutics Announces Positive Final Results from Target Enrollment in the ALPHA-STAR Phase 1b/2 Trial of Navenibart for HAE", "publisher": "Business Wire", "link": "https://finance.yahoo.com/news/astria-therapeutics-announces-positive-final-130000824.html", "providerPublishTime": 1733922000, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/ypVi2N4c293_8XpTvuNsiQ--~B/aD0xMTg5O3c9Mzk0NTthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/business-wire.com/bf0719ea990900f9aabb4a33d1051f17", "width": 3945, "height": 1189, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/6pVhpx9XQKpEn3WyhYxWPQ--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/bf0719ea990900f9aabb4a33d1051f17", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["ATXS"]}, {"uuid": "2b93000a-c00d-3f1e-84d1-3507b838bede", "title": "Astria Therapeutics Announces FDA Clearance of IND Application for STAR-0310, a Monoclonal Antibody OX40 Antagonist for the Treatment of Atopic Dermatitis", "publisher": "Business Wire", "link": "https://finance.yahoo.com/news/astria-therapeutics-announces-fda-clearance-130000723.html", "providerPublishTime": 1733835600, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/xkrY_Hh8UjPCfKHv63X8xg--~B/aD0xMTg5O3c9Mzk0NTthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/business-wire.com/04235dc23ce5a7c9b0fbf5d47c9dba83", "width": 3945, "height": 1189, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/Xj4KSafvGCShsD3682B78A--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/04235dc23ce5a7c9b0fbf5d47c9dba83", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["ATXS"]}, {"uuid": "d285f05c-4f71-3d3a-b870-21ae4a930c10", "title": "Astria Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update", "publisher": "Business Wire", "link": "https://finance.yahoo.com/news/astria-therapeutics-reports-third-quarter-211000692.html", "providerPublishTime": 1731532200, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/uXk_PvET5p5_HxEW15TgOQ--~B/aD0xMTg5O3c9Mzk0NTthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/business-wire.com/335ab08b85baaf190a425807af0fc82c", "width": 3945, "height": 1189, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/u3Pz.b.2WOTn2YioOsv8ug--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/335ab08b85baaf190a425807af0fc82c", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["ATXS"]}]